Publications by authors named "Paul E Newton"

Standards for talking and thinking about validity have been promulgated in North America for decades. In 1954 two foundational standards were announced: (a) Thou shalt not refer to "the validity of the test" and (b) thou shalt use validity modifier labels, such as "content validity" or "predictive validity." Subsequently, in 1985, the latter became, thou shalt not use validity modifier labels.

View Article and Find Full Text PDF

EXPAREL (bupivacaine extended-release liposome injection), DepoFoam bupivacaine, is in development for prolonged postsurgical analgesia. Repeat-dose toxicity studies were conducted in rabbits and dogs to compare the potential local and systemic toxicities of EXPAREL and bupivacaine HCl (Bsol), and the reversibility of any effects. Dogs tolerated much larger doses than rabbits.

View Article and Find Full Text PDF

Objective: DepoFoam bupivacaine (DB) is in development for prolonged postoperative analgesia. Studies were conducted to evaluate the potential local and systemic toxicity and any effect on wound healing after wound infiltration.

Methods: The model simulates an inguinal hernia (skin incision ∼2.

View Article and Find Full Text PDF

Asphalt (bitumen) fume condensates collected from the headspace above paving and Type III built up roofing asphalt (BURA) tanks were evaluated in two-year dermal carcinogenicity assays in male C3H/HeNCrl mice. A third sample was generated from the BURA using a NIOSH laboratory generation method. Similar to earlier NIOSH studies, the BURA fume condensates were applied dermally in mineral oil twice per week; the paving sample was applied 7 days/week for a total weekly dose of 50 mg/wk in both studies.

View Article and Find Full Text PDF

Background/aims: GBR12909 has been reported to possess anticonvulsant activity with focal brain perfusion to the hippocampus of pilocarpine, although an earlier publication suggested any anticonvulsant effects were only mild. Here we further explored the anticonvulsant potential of GBR12909 with a suite of anticonvulsant assays in both zebrafish and mammals and then explored whether it possessed any QT effects which might limit clinical utility.

Methods: We assessed the anticonvulsant effects of GBR12909 in zebrafish pentylenetetrazole (PTZ), mammalian maximal electroshock and PTZ models of generalized epilepsy and a rodent hippocampal kindling model.

View Article and Find Full Text PDF

Methylethylketoxime, also known as MEKO or 2-butanone oxime (CAS No. 96-29-7), is a clear, colorless to light yellow liquid at room temperature. It is an industrial antioxidant used as an antiskinning agent in alkyd paint, an industrial blocking agent for urethane polymers, and a corrosion inhibitor in industrial boilers, and can be found in some adhesives and silicone caulking products.

View Article and Find Full Text PDF